Disease Overview：Crohn's disease（CD）
Crohn’s disease is a chronic, immune-mediated inflammatory bowel disease (IBD) characterized by transmural inflammation that can affect any segment of the gastrointestinal tract—from mouth to anus—with ileocolonic involvement being most common. Clinical manifestations include persistent diarrhea, abdominal pain, weight loss, fatigue, and extraintestinal manifestations such as arthralgia, uveitis, or erythema nodosum. Diagnosis relies on integrated assessment: clinical evaluation, endoscopic findings (e.g., skip lesions, cobblestoning, aphthous ulcers), histopathology, cross-sectional imaging (MRI enterography or CT enterography), and serologic markers (e.g., anti-Saccharomyces cerevisiae antibodies). Management follows a step-up or top-down strategy, incorporating immunomodulators (azathioprine, methotrexate), biologics (anti-TNF agents like infliximab and adalimumab, integrin inhibitors such as vedolizumab, and newer IL-23 antagonists), and, when indicated, surgical resection for strictures or fistulae. Long-term monitoring focuses on mucosal healing, prevention of complications—including colorectal cancer—and maintenance of quality of life.
China offers distinct advantages for Crohn’s disease management: its tertiary hospitals house nationally certified IBD centers with multidisciplinary teams experienced in complex phenotypes and refractory cases. Advanced diagnostic capabilities—including high-resolution capsule endoscopy, fecal calprotectin quantification, and therapeutic drug monitoring—are widely available. Chinese gastroenterologists actively contribute to global clinical trials and have published robust real-world evidence demonstrating sustained remission rates exceeding 65% at one year with optimized biologic regimens. Treatment costs are typically 40–60% lower than in the US or Western Europe—without compromising efficacy or safety—due to streamlined regulatory pathways and domestic biosimilar adoption. As a dedicated medical tourism agency, we facilitate seamless access for international patients: coordinating appointments with accredited IBD specialists, verifying hospital credentials, providing itemized, transparent pricing in advance, arranging visa support, accommodation, and post-treatment follow-up—all tailored to individual clinical needs and cultural preferences.
Medical Treatment Guide
Treatment Options & Itemized Cost Breakdown: Crohn’s Disease (Gastroenterology)
Non-Surgical / Medical Management
*Target criteria:* Mild–moderate active disease, steroid-dependent or steroid-refractory cases, postoperative prophylaxis, maintenance of remission.
- •First-line (Mild–Moderate):
- Budesonide (oral, ileal-release): ¥420–¥650/course (8 weeks) ($60–$93) - *Pre-treatment labs:* CBC, CRP, LFTs, ESR, calprotectin (stool): ¥320 ($46)
- •Second-line (Moderate–Severe or Refractory):
- Methotrexate (SC/injection): ¥240–¥360/month + monthly LFT monitoring (¥120): ($34–$51/month + $17)
- •Biologics (Severe/Refractory/Fistulizing):
- Adalimumab (SC, self-injectable): ¥3,200–¥4,100/month → ¥38,400–¥49,200/year ($5,490–$7,030) - Vedolizumab (IV): ¥3,500–¥4,300/dose (q8w) → ¥21,000–¥25,800/year ($3,000–$3,690) - *Required baseline workup:* TB screening (IGRA ¥280), HBV/HCV serology (¥360), chest X-ray (¥150), ECG (¥120): Total $127
Surgical / Interventional Options
*Eligibility:* Strictures unresponsive to medical therapy, fistulas (entero-enteric/enterocutaneous), abscesses, perforation, hemorrhage, or dysplasia/cancer surveillance.
- •Laparoscopic Ileocecal Resection: ¥28,000–¥42,000 ($4,000–$6,000)
- •Strictureplasty (for multiple short strictures): ¥22,000–¥35,000 ($3,140–$5,000)
- •Perianal Fistula Seton Placement + Drainage: ¥12,000–¥18,000 ($1,710–$2,570)
- •Preoperative Workup (mandatory): CT enterography (¥1,200), colonoscopy + biopsy (¥2,100), nutritional assessment (albumin/prealbumin, ¥180), cardiopulmonary evaluation (ECG + echo if indicated, ¥850): Total $2,330
Special/Complex Scenarios
- •Fistulizing Perianal Disease (with MRI fistulogram): ¥1,600 ($229) + biologic escalation (adalimumab ± infliximab) → annual cost $5,500–$8,200
- •Pediatric-Onset (<18 years): Growth monitoring + bone density (DEXA, ¥480, $69) + lower-dose biologics; infliximab dosing adjusted → annual cost $2,200–$3,800
- •Postoperative Recurrence Prophylaxis: Early thiopurine or vedolizumab initiation → adds ¥1,800–¥4,500/year ($257–$643)
Quick Selection Guide
- •Young adult (18–35), budget-constrained, mild disease: Start with budesonide + mesalamine ($77–$108/month)
- •Middle-aged, moderate–severe, comorbid diabetes/hypertension: Vedolizumab (gut-selective, low systemic risk) → $3,000–$3,700/year
- •Elderly (>65), stricturing, limited mobility: Laparoscopic resection preferred over long-term biologics → $4,000–$6,000 one-time
- •Pediatric patient with growth failure: Infliximab + nutrition support → $2,200–$3,800/year, plus DEXA and endocrine consult ($69–$120)
Pricing & Service Differences: International / VIP Dept vs. Regular Clinic
International Medical Services (IMS / VIP Departments) at Grade-3A public hospitals and private international clinics operate under self-regulated VIP fee schedules. Fees are higher than standard public clinics (which are subsidized solely for domestic citizens and do not accept overseas insurances). In exchange, international patients receive 6 exclusive medical privileges:
Recommended Hospitals
Explore selected Grade 3A public hospitals in China with rich clinical experience for this condition:
🌴 Recommended Crohn's disease Medical Vacation Packages
Curated transparent all-inclusive packages combining Crohn's disease treatment with China top medical destinations:
